Frontiers in public health · 2026
Budget impact analysis of the introduction of ranibizumab's biosimilar to the Jordanian joint procurement system.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hamida Jalal Abu, Alkhatib Nimer S, Hammour Khawla Abu, Halloush Shiraz, Kurdi Amanj, Balkhi Bander, Alfayez Osamah M, Mousa Rimal
Аннотация
INTRODUCTION: The adoption of biologic therapies imposes a substantial financial burden on the Jordanian healthcare system. ranibizumab is prescribed for various retinal disorders, and its associated costs are considerable. The introduction of biosimilars is beneficial in retaining desired clinical parameters while providing cost relief and enhanced access to patients.
OBJECTIVE: To examine the budget impact and expanded access of switching to ranibizumab's biosimilar for the management of retinal diseases in guideline-based practice and in real-world practice in Jordan.
METHOD: A 4-year budget impact analysis from Jordanian public sector payer's sector was performed (2023 to 2026) that included patient prevalence and incidence, average ranibizumab dose per year, and anticipated shifts in the market share of ranibizumab and aflibercept. The model took into account the anticipated price erosion of the biosimilar in 2025 and 2026. Sensitivity analyses were performed to assess the effect of changes in uptake rates, price, and market share.
RESULTS: The annual cost savings per patient when switching from aflibercept to ranibizumab's biosimilar were from 20.55 JOD (Jordanian Dinar) to 1519.93 JOD, translating to a percentage saving of 2.68 to 35.12% across the various scenarios and indications. The total budget impact ranged widely from 6.9 M JOD to 21.2 M JOD based on treatment regimens adjusted to current practice, PRN (Pro re nata), or T&E (Treat and extend). Patient access improved between 2.75 to 124.76% in the different scenarios.
CONCLUSION: The introduction of ranibizumab's biosimilar significantly reduces the expenditures and enhances treatment access.
OBJECTIVE: To examine the budget impact and expanded access of switching to ranibizumab's biosimilar for the management of retinal diseases in guideline-based practice and in real-world practice in Jordan.
METHOD: A 4-year budget impact analysis from Jordanian public sector payer's sector was performed (2023 to 2026) that included patient prevalence and incidence, average ranibizumab dose per year, and anticipated shifts in the market share of ranibizumab and aflibercept. The model took into account the anticipated price erosion of the biosimilar in 2025 and 2026. Sensitivity analyses were performed to assess the effect of changes in uptake rates, price, and market share.
RESULTS: The annual cost savings per patient when switching from aflibercept to ranibizumab's biosimilar were from 20.55 JOD (Jordanian Dinar) to 1519.93 JOD, translating to a percentage saving of 2.68 to 35.12% across the various scenarios and indications. The total budget impact ranged widely from 6.9 M JOD to 21.2 M JOD based on treatment regimens adjusted to current practice, PRN (Pro re nata), or T&E (Treat and extend). Patient access improved between 2.75 to 124.76% in the different scenarios.
CONCLUSION: The introduction of ranibizumab's biosimilar significantly reduces the expenditures and enhances treatment access.